RecruitingNCT07411716
Pediatric Evaluation and Registry for Liver Cholestasis in Canada
Studying Alagille syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Children's Hospital of Eastern Ontario
- Enrollment
- 220 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2031
Study locations (13)
- Alberta Children's Hospital, Calgary, Alberta, Canada
- Stollery Children's Hospital, Edmonton, Alberta, Canada
- BC Children's Hospital, Vancouver, British Columbia, Canada
- HSC Winnipeg Children's Hospital, Winnipeg, Manitoba, Canada
- Janeway Children's Health and Rehabilitation Centre, St. John's, Newfoundland and Labrador, Canada
- Children's Hospital IWK Health Centre, Halifax, Nova Scotia, Canada
- McMaster Children's Hospital, Hamilton, Ontario, Canada
- Children's Hospital LHSC, London, Ontario, Canada
- Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada
- CHU Sainte-Justine, Montreal, Quebec, Canada
- Montreal Children's Hospital, Montreal, Quebec, Canada
- CHU de Quebec - Universite Laval (Centre Mere-Enfant Soleil), Qubec City, Quebec, Canada
- Jim Pattison Children's Hospital, Saskatoon, Saskatchewan, Canada
Collaborators
Mirum Pharmaceuticals, Inc. · medison pharma
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07411716 on ClinicalTrials.govOther trials for Alagille syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07293897A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)Takeda
- RECRUITINGPHASE4NCT07290257Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome in the European Union (LEAP-EU)Mirum Pharmaceuticals, Inc.
- RECRUITINGNCT06850038A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing TreatmentIpsen
- RECRUITINGNCT06193928Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)Mirum Pharmaceuticals, Inc.
- RECRUITINGPHASE3NCT05035030Long-term Safety and Efficacy of Odevixibat in Patients With Alagille SyndromeAlbireo, an Ipsen Company